开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2197400, encodeId=8a42219e400e0, content=偏重的研究方向：靶向药物;药学 经验分享：6天拒了，日本编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9f0d5508964, createdName=ms7000000724576513, createdTime=Mon Apr 08 16:03:00 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2092620, encodeId=8ac7209262069, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：8月1号投稿 8月9号送审 8月28号初审意见回来，三个审稿人都挺友好，补了个溶血性实验，重拍了电镜，小修了语法9月13日返修回杂志。 10月4日二审意见返回来，要求小修，5号修改完成提交后，10月6日接受 是韩国编辑，挺友好的，实验室由他接手的文章已中了两篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e085589992, createdName=ms6000001711124234, createdTime=Sun Oct 09 10:03:52 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177999, encodeId=9cbd21e799917, content=好倒霉哦！我看我是个日本编辑Fumiyoshi Yamashita.，刚刚分配的，该不会也不友好吧！唉！静等吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2be5614278, createdName=ms4000000786391399, createdTime=Fri Dec 29 14:25:17 CST 2023, time=2023-12-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2118278, encodeId=7b8421182e883, content=千万别投这个，超级浪费时间，我是被分配到日本编辑，with editor 2个多星期，没有送审，最后还是直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=70d05574935, createdName=ms9000000173292023, createdTime=Wed Mar 08 14:24:38 CST 2023, time=2023-03-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2141800, encodeId=7a71214180039, content=日本编辑真的。。。。快两周，不送审，要拒了，无语 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49bb6565860, createdName=ms7000000230836793, createdTime=Fri Jun 09 00:48:09 CST 2023, time=2023-06-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1217328, encodeId=c4ec121e3288c, content=请问这个杂志快不快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0ce8104658, createdName=ms4000000757843752, createdTime=Fri May 06 12:30:02 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922387, encodeId=027c92238e62, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：小硕第一次投IJP,一审小修, 两个审稿意见,一个拒了, 一个提了点关于补充文献的问题, 然后二审有惊无险, 二审required review completed后又under review 3天仲裁去了, 随后接受 时间节点: Received 17 November 2020, Revised 5 January 2021, Accepted 31 January 2021, Available online 2 February 2021., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lLjNEmtiacOgliciaHOQ51Bkuhdy65x8Ciaax4S8cLBObsqrXYBiacsyBmmLhN6ictV4TWVVFPQCcKvN8dcEhSKPicb8w/132, createdBy=94812480651, createdName=lbhaihyh, createdTime=Wed Feb 03 09:09:53 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089655, encodeId=03311089655f2, content=关键词筛选有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089656, encodeId=94de10896563b, content=关键词最多不能超过多少个？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969471, encodeId=35ab9694e186, content=想问一下是否收网络药理学文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a3a5400973, createdName=背包客-Y, createdTime=Sat May 29 17:08:41 CST 2021, time=2021-05-29, status=1, ipAttribution=)]

2024-04-08 ms7000000724576513 来自安徽省

偏重的研究方向：靶向药物;药学
经验分享：6天拒了，日本编辑

65 0

[GetPortalCommentsPageByObjectIdResponse(id=2197400, encodeId=8a42219e400e0, content=偏重的研究方向：靶向药物;药学 经验分享：6天拒了，日本编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9f0d5508964, createdName=ms7000000724576513, createdTime=Mon Apr 08 16:03:00 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2092620, encodeId=8ac7209262069, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：8月1号投稿 8月9号送审 8月28号初审意见回来，三个审稿人都挺友好，补了个溶血性实验，重拍了电镜，小修了语法9月13日返修回杂志。 10月4日二审意见返回来，要求小修，5号修改完成提交后，10月6日接受 是韩国编辑，挺友好的，实验室由他接手的文章已中了两篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e085589992, createdName=ms6000001711124234, createdTime=Sun Oct 09 10:03:52 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177999, encodeId=9cbd21e799917, content=好倒霉哦！我看我是个日本编辑Fumiyoshi Yamashita.，刚刚分配的，该不会也不友好吧！唉！静等吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2be5614278, createdName=ms4000000786391399, createdTime=Fri Dec 29 14:25:17 CST 2023, time=2023-12-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2118278, encodeId=7b8421182e883, content=千万别投这个，超级浪费时间，我是被分配到日本编辑，with editor 2个多星期，没有送审，最后还是直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=70d05574935, createdName=ms9000000173292023, createdTime=Wed Mar 08 14:24:38 CST 2023, time=2023-03-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2141800, encodeId=7a71214180039, content=日本编辑真的。。。。快两周，不送审，要拒了，无语 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49bb6565860, createdName=ms7000000230836793, createdTime=Fri Jun 09 00:48:09 CST 2023, time=2023-06-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1217328, encodeId=c4ec121e3288c, content=请问这个杂志快不快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0ce8104658, createdName=ms4000000757843752, createdTime=Fri May 06 12:30:02 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922387, encodeId=027c92238e62, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：小硕第一次投IJP,一审小修, 两个审稿意见,一个拒了, 一个提了点关于补充文献的问题, 然后二审有惊无险, 二审required review completed后又under review 3天仲裁去了, 随后接受 时间节点: Received 17 November 2020, Revised 5 January 2021, Accepted 31 January 2021, Available online 2 February 2021., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lLjNEmtiacOgliciaHOQ51Bkuhdy65x8Ciaax4S8cLBObsqrXYBiacsyBmmLhN6ictV4TWVVFPQCcKvN8dcEhSKPicb8w/132, createdBy=94812480651, createdName=lbhaihyh, createdTime=Wed Feb 03 09:09:53 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089655, encodeId=03311089655f2, content=关键词筛选有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089656, encodeId=94de10896563b, content=关键词最多不能超过多少个？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969471, encodeId=35ab9694e186, content=想问一下是否收网络药理学文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a3a5400973, createdName=背包客-Y, createdTime=Sat May 29 17:08:41 CST 2021, time=2021-05-29, status=1, ipAttribution=)]

2022-10-09 ms6000001711124234

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：纳米药物;脂质体
经验分享：8月1号投稿
8月9号送审
8月28号初审意见回来，三个审稿人都挺友好，补了个溶血性实验，重拍了电镜，小修了语法9月13日返修回杂志。
10月4日二审意见返回来，要求小修，5号修改完成提交后，10月6日接受
是韩国编辑，挺友好的，实验室由他接手的文章已中了两篇

123 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2197400, encodeId=8a42219e400e0, content=偏重的研究方向：靶向药物;药学 经验分享：6天拒了，日本编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9f0d5508964, createdName=ms7000000724576513, createdTime=Mon Apr 08 16:03:00 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2092620, encodeId=8ac7209262069, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：8月1号投稿 8月9号送审 8月28号初审意见回来，三个审稿人都挺友好，补了个溶血性实验，重拍了电镜，小修了语法9月13日返修回杂志。 10月4日二审意见返回来，要求小修，5号修改完成提交后，10月6日接受 是韩国编辑，挺友好的，实验室由他接手的文章已中了两篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e085589992, createdName=ms6000001711124234, createdTime=Sun Oct 09 10:03:52 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177999, encodeId=9cbd21e799917, content=好倒霉哦！我看我是个日本编辑Fumiyoshi Yamashita.，刚刚分配的，该不会也不友好吧！唉！静等吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2be5614278, createdName=ms4000000786391399, createdTime=Fri Dec 29 14:25:17 CST 2023, time=2023-12-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2118278, encodeId=7b8421182e883, content=千万别投这个，超级浪费时间，我是被分配到日本编辑，with editor 2个多星期，没有送审，最后还是直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=70d05574935, createdName=ms9000000173292023, createdTime=Wed Mar 08 14:24:38 CST 2023, time=2023-03-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2141800, encodeId=7a71214180039, content=日本编辑真的。。。。快两周，不送审，要拒了，无语 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49bb6565860, createdName=ms7000000230836793, createdTime=Fri Jun 09 00:48:09 CST 2023, time=2023-06-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1217328, encodeId=c4ec121e3288c, content=请问这个杂志快不快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0ce8104658, createdName=ms4000000757843752, createdTime=Fri May 06 12:30:02 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922387, encodeId=027c92238e62, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：小硕第一次投IJP,一审小修, 两个审稿意见,一个拒了, 一个提了点关于补充文献的问题, 然后二审有惊无险, 二审required review completed后又under review 3天仲裁去了, 随后接受 时间节点: Received 17 November 2020, Revised 5 January 2021, Accepted 31 January 2021, Available online 2 February 2021., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lLjNEmtiacOgliciaHOQ51Bkuhdy65x8Ciaax4S8cLBObsqrXYBiacsyBmmLhN6ictV4TWVVFPQCcKvN8dcEhSKPicb8w/132, createdBy=94812480651, createdName=lbhaihyh, createdTime=Wed Feb 03 09:09:53 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089655, encodeId=03311089655f2, content=关键词筛选有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089656, encodeId=94de10896563b, content=关键词最多不能超过多少个？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969471, encodeId=35ab9694e186, content=想问一下是否收网络药理学文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a3a5400973, createdName=背包客-Y, createdTime=Sat May 29 17:08:41 CST 2021, time=2021-05-29, status=1, ipAttribution=)]

2023-12-29 ms4000000786391399 来自湖北省

好倒霉哦！我看我是个日本编辑Fumiyoshi Yamashita.，刚刚分配的，该不会也不友好吧！唉！静等吧！

62 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2197400, encodeId=8a42219e400e0, content=偏重的研究方向：靶向药物;药学 经验分享：6天拒了，日本编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9f0d5508964, createdName=ms7000000724576513, createdTime=Mon Apr 08 16:03:00 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2092620, encodeId=8ac7209262069, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：8月1号投稿 8月9号送审 8月28号初审意见回来，三个审稿人都挺友好，补了个溶血性实验，重拍了电镜，小修了语法9月13日返修回杂志。 10月4日二审意见返回来，要求小修，5号修改完成提交后，10月6日接受 是韩国编辑，挺友好的，实验室由他接手的文章已中了两篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e085589992, createdName=ms6000001711124234, createdTime=Sun Oct 09 10:03:52 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177999, encodeId=9cbd21e799917, content=好倒霉哦！我看我是个日本编辑Fumiyoshi Yamashita.，刚刚分配的，该不会也不友好吧！唉！静等吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2be5614278, createdName=ms4000000786391399, createdTime=Fri Dec 29 14:25:17 CST 2023, time=2023-12-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2118278, encodeId=7b8421182e883, content=千万别投这个，超级浪费时间，我是被分配到日本编辑，with editor 2个多星期，没有送审，最后还是直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=70d05574935, createdName=ms9000000173292023, createdTime=Wed Mar 08 14:24:38 CST 2023, time=2023-03-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2141800, encodeId=7a71214180039, content=日本编辑真的。。。。快两周，不送审，要拒了，无语 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49bb6565860, createdName=ms7000000230836793, createdTime=Fri Jun 09 00:48:09 CST 2023, time=2023-06-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1217328, encodeId=c4ec121e3288c, content=请问这个杂志快不快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0ce8104658, createdName=ms4000000757843752, createdTime=Fri May 06 12:30:02 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922387, encodeId=027c92238e62, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：小硕第一次投IJP,一审小修, 两个审稿意见,一个拒了, 一个提了点关于补充文献的问题, 然后二审有惊无险, 二审required review completed后又under review 3天仲裁去了, 随后接受 时间节点: Received 17 November 2020, Revised 5 January 2021, Accepted 31 January 2021, Available online 2 February 2021., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lLjNEmtiacOgliciaHOQ51Bkuhdy65x8Ciaax4S8cLBObsqrXYBiacsyBmmLhN6ictV4TWVVFPQCcKvN8dcEhSKPicb8w/132, createdBy=94812480651, createdName=lbhaihyh, createdTime=Wed Feb 03 09:09:53 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089655, encodeId=03311089655f2, content=关键词筛选有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089656, encodeId=94de10896563b, content=关键词最多不能超过多少个？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969471, encodeId=35ab9694e186, content=想问一下是否收网络药理学文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a3a5400973, createdName=背包客-Y, createdTime=Sat May 29 17:08:41 CST 2021, time=2021-05-29, status=1, ipAttribution=)]

2023-03-08 ms9000000173292023 来自湖南省

千万别投这个，超级浪费时间，我是被分配到日本编辑，with editor 2个多星期，没有送审，最后还是直接拒稿了

97 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2197400, encodeId=8a42219e400e0, content=偏重的研究方向：靶向药物;药学 经验分享：6天拒了，日本编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9f0d5508964, createdName=ms7000000724576513, createdTime=Mon Apr 08 16:03:00 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2092620, encodeId=8ac7209262069, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：8月1号投稿 8月9号送审 8月28号初审意见回来，三个审稿人都挺友好，补了个溶血性实验，重拍了电镜，小修了语法9月13日返修回杂志。 10月4日二审意见返回来，要求小修，5号修改完成提交后，10月6日接受 是韩国编辑，挺友好的，实验室由他接手的文章已中了两篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e085589992, createdName=ms6000001711124234, createdTime=Sun Oct 09 10:03:52 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177999, encodeId=9cbd21e799917, content=好倒霉哦！我看我是个日本编辑Fumiyoshi Yamashita.，刚刚分配的，该不会也不友好吧！唉！静等吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2be5614278, createdName=ms4000000786391399, createdTime=Fri Dec 29 14:25:17 CST 2023, time=2023-12-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2118278, encodeId=7b8421182e883, content=千万别投这个，超级浪费时间，我是被分配到日本编辑，with editor 2个多星期，没有送审，最后还是直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=70d05574935, createdName=ms9000000173292023, createdTime=Wed Mar 08 14:24:38 CST 2023, time=2023-03-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2141800, encodeId=7a71214180039, content=日本编辑真的。。。。快两周，不送审，要拒了，无语 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49bb6565860, createdName=ms7000000230836793, createdTime=Fri Jun 09 00:48:09 CST 2023, time=2023-06-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1217328, encodeId=c4ec121e3288c, content=请问这个杂志快不快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0ce8104658, createdName=ms4000000757843752, createdTime=Fri May 06 12:30:02 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922387, encodeId=027c92238e62, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：小硕第一次投IJP,一审小修, 两个审稿意见,一个拒了, 一个提了点关于补充文献的问题, 然后二审有惊无险, 二审required review completed后又under review 3天仲裁去了, 随后接受 时间节点: Received 17 November 2020, Revised 5 January 2021, Accepted 31 January 2021, Available online 2 February 2021., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lLjNEmtiacOgliciaHOQ51Bkuhdy65x8Ciaax4S8cLBObsqrXYBiacsyBmmLhN6ictV4TWVVFPQCcKvN8dcEhSKPicb8w/132, createdBy=94812480651, createdName=lbhaihyh, createdTime=Wed Feb 03 09:09:53 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089655, encodeId=03311089655f2, content=关键词筛选有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089656, encodeId=94de10896563b, content=关键词最多不能超过多少个？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969471, encodeId=35ab9694e186, content=想问一下是否收网络药理学文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a3a5400973, createdName=背包客-Y, createdTime=Sat May 29 17:08:41 CST 2021, time=2021-05-29, status=1, ipAttribution=)]

2023-06-09 ms7000000230836793 来自湖北省

日本编辑真的。。。。快两周，不送审，要拒了，无语

91 0

[GetPortalCommentsPageByObjectIdResponse(id=2197400, encodeId=8a42219e400e0, content=偏重的研究方向：靶向药物;药学 经验分享：6天拒了，日本编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9f0d5508964, createdName=ms7000000724576513, createdTime=Mon Apr 08 16:03:00 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2092620, encodeId=8ac7209262069, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：8月1号投稿 8月9号送审 8月28号初审意见回来，三个审稿人都挺友好，补了个溶血性实验，重拍了电镜，小修了语法9月13日返修回杂志。 10月4日二审意见返回来，要求小修，5号修改完成提交后，10月6日接受 是韩国编辑，挺友好的，实验室由他接手的文章已中了两篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e085589992, createdName=ms6000001711124234, createdTime=Sun Oct 09 10:03:52 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177999, encodeId=9cbd21e799917, content=好倒霉哦！我看我是个日本编辑Fumiyoshi Yamashita.，刚刚分配的，该不会也不友好吧！唉！静等吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2be5614278, createdName=ms4000000786391399, createdTime=Fri Dec 29 14:25:17 CST 2023, time=2023-12-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2118278, encodeId=7b8421182e883, content=千万别投这个，超级浪费时间，我是被分配到日本编辑，with editor 2个多星期，没有送审，最后还是直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=70d05574935, createdName=ms9000000173292023, createdTime=Wed Mar 08 14:24:38 CST 2023, time=2023-03-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2141800, encodeId=7a71214180039, content=日本编辑真的。。。。快两周，不送审，要拒了，无语 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49bb6565860, createdName=ms7000000230836793, createdTime=Fri Jun 09 00:48:09 CST 2023, time=2023-06-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1217328, encodeId=c4ec121e3288c, content=请问这个杂志快不快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0ce8104658, createdName=ms4000000757843752, createdTime=Fri May 06 12:30:02 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922387, encodeId=027c92238e62, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：小硕第一次投IJP,一审小修, 两个审稿意见,一个拒了, 一个提了点关于补充文献的问题, 然后二审有惊无险, 二审required review completed后又under review 3天仲裁去了, 随后接受 时间节点: Received 17 November 2020, Revised 5 January 2021, Accepted 31 January 2021, Available online 2 February 2021., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lLjNEmtiacOgliciaHOQ51Bkuhdy65x8Ciaax4S8cLBObsqrXYBiacsyBmmLhN6ictV4TWVVFPQCcKvN8dcEhSKPicb8w/132, createdBy=94812480651, createdName=lbhaihyh, createdTime=Wed Feb 03 09:09:53 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089655, encodeId=03311089655f2, content=关键词筛选有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089656, encodeId=94de10896563b, content=关键词最多不能超过多少个？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969471, encodeId=35ab9694e186, content=想问一下是否收网络药理学文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a3a5400973, createdName=背包客-Y, createdTime=Sat May 29 17:08:41 CST 2021, time=2021-05-29, status=1, ipAttribution=)]

2022-05-06 ms4000000757843752

请问这个杂志快不快

97 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2197400, encodeId=8a42219e400e0, content=偏重的研究方向：靶向药物;药学 经验分享：6天拒了，日本编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9f0d5508964, createdName=ms7000000724576513, createdTime=Mon Apr 08 16:03:00 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2092620, encodeId=8ac7209262069, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：8月1号投稿 8月9号送审 8月28号初审意见回来，三个审稿人都挺友好，补了个溶血性实验，重拍了电镜，小修了语法9月13日返修回杂志。 10月4日二审意见返回来，要求小修，5号修改完成提交后，10月6日接受 是韩国编辑，挺友好的，实验室由他接手的文章已中了两篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e085589992, createdName=ms6000001711124234, createdTime=Sun Oct 09 10:03:52 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177999, encodeId=9cbd21e799917, content=好倒霉哦！我看我是个日本编辑Fumiyoshi Yamashita.，刚刚分配的，该不会也不友好吧！唉！静等吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2be5614278, createdName=ms4000000786391399, createdTime=Fri Dec 29 14:25:17 CST 2023, time=2023-12-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2118278, encodeId=7b8421182e883, content=千万别投这个，超级浪费时间，我是被分配到日本编辑，with editor 2个多星期，没有送审，最后还是直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=70d05574935, createdName=ms9000000173292023, createdTime=Wed Mar 08 14:24:38 CST 2023, time=2023-03-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2141800, encodeId=7a71214180039, content=日本编辑真的。。。。快两周，不送审，要拒了，无语 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49bb6565860, createdName=ms7000000230836793, createdTime=Fri Jun 09 00:48:09 CST 2023, time=2023-06-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1217328, encodeId=c4ec121e3288c, content=请问这个杂志快不快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0ce8104658, createdName=ms4000000757843752, createdTime=Fri May 06 12:30:02 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922387, encodeId=027c92238e62, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：小硕第一次投IJP,一审小修, 两个审稿意见,一个拒了, 一个提了点关于补充文献的问题, 然后二审有惊无险, 二审required review completed后又under review 3天仲裁去了, 随后接受 时间节点: Received 17 November 2020, Revised 5 January 2021, Accepted 31 January 2021, Available online 2 February 2021., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lLjNEmtiacOgliciaHOQ51Bkuhdy65x8Ciaax4S8cLBObsqrXYBiacsyBmmLhN6ictV4TWVVFPQCcKvN8dcEhSKPicb8w/132, createdBy=94812480651, createdName=lbhaihyh, createdTime=Wed Feb 03 09:09:53 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089655, encodeId=03311089655f2, content=关键词筛选有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089656, encodeId=94de10896563b, content=关键词最多不能超过多少个？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969471, encodeId=35ab9694e186, content=想问一下是否收网络药理学文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a3a5400973, createdName=背包客-Y, createdTime=Sat May 29 17:08:41 CST 2021, time=2021-05-29, status=1, ipAttribution=)]

2021-02-03 lbhaihyh

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：纳米药物;脂质体
经验分享：小硕第一次投IJP,一审小修, 两个审稿意见,一个拒了, 一个提了点关于补充文献的问题, 然后二审有惊无险, 二审required review completed后又under review 3天仲裁去了, 随后接受
时间节点:
Received 17 November 2020,
Revised 5 January 2021,
Accepted 31 January 2021,
Available online 2 February 2021.

225 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2197400, encodeId=8a42219e400e0, content=偏重的研究方向：靶向药物;药学 经验分享：6天拒了，日本编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9f0d5508964, createdName=ms7000000724576513, createdTime=Mon Apr 08 16:03:00 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2092620, encodeId=8ac7209262069, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：8月1号投稿 8月9号送审 8月28号初审意见回来，三个审稿人都挺友好，补了个溶血性实验，重拍了电镜，小修了语法9月13日返修回杂志。 10月4日二审意见返回来，要求小修，5号修改完成提交后，10月6日接受 是韩国编辑，挺友好的，实验室由他接手的文章已中了两篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e085589992, createdName=ms6000001711124234, createdTime=Sun Oct 09 10:03:52 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177999, encodeId=9cbd21e799917, content=好倒霉哦！我看我是个日本编辑Fumiyoshi Yamashita.，刚刚分配的，该不会也不友好吧！唉！静等吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2be5614278, createdName=ms4000000786391399, createdTime=Fri Dec 29 14:25:17 CST 2023, time=2023-12-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2118278, encodeId=7b8421182e883, content=千万别投这个，超级浪费时间，我是被分配到日本编辑，with editor 2个多星期，没有送审，最后还是直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=70d05574935, createdName=ms9000000173292023, createdTime=Wed Mar 08 14:24:38 CST 2023, time=2023-03-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2141800, encodeId=7a71214180039, content=日本编辑真的。。。。快两周，不送审，要拒了，无语 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49bb6565860, createdName=ms7000000230836793, createdTime=Fri Jun 09 00:48:09 CST 2023, time=2023-06-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1217328, encodeId=c4ec121e3288c, content=请问这个杂志快不快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0ce8104658, createdName=ms4000000757843752, createdTime=Fri May 06 12:30:02 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922387, encodeId=027c92238e62, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：小硕第一次投IJP,一审小修, 两个审稿意见,一个拒了, 一个提了点关于补充文献的问题, 然后二审有惊无险, 二审required review completed后又under review 3天仲裁去了, 随后接受 时间节点: Received 17 November 2020, Revised 5 January 2021, Accepted 31 January 2021, Available online 2 February 2021., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lLjNEmtiacOgliciaHOQ51Bkuhdy65x8Ciaax4S8cLBObsqrXYBiacsyBmmLhN6ictV4TWVVFPQCcKvN8dcEhSKPicb8w/132, createdBy=94812480651, createdName=lbhaihyh, createdTime=Wed Feb 03 09:09:53 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089655, encodeId=03311089655f2, content=关键词筛选有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089656, encodeId=94de10896563b, content=关键词最多不能超过多少个？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969471, encodeId=35ab9694e186, content=想问一下是否收网络药理学文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a3a5400973, createdName=背包客-Y, createdTime=Sat May 29 17:08:41 CST 2021, time=2021-05-29, status=1, ipAttribution=)]

2021-12-28 rayms

关键词筛选有什么要求？

131 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2197400, encodeId=8a42219e400e0, content=偏重的研究方向：靶向药物;药学 经验分享：6天拒了，日本编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9f0d5508964, createdName=ms7000000724576513, createdTime=Mon Apr 08 16:03:00 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2092620, encodeId=8ac7209262069, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：8月1号投稿 8月9号送审 8月28号初审意见回来，三个审稿人都挺友好，补了个溶血性实验，重拍了电镜，小修了语法9月13日返修回杂志。 10月4日二审意见返回来，要求小修，5号修改完成提交后，10月6日接受 是韩国编辑，挺友好的，实验室由他接手的文章已中了两篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e085589992, createdName=ms6000001711124234, createdTime=Sun Oct 09 10:03:52 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177999, encodeId=9cbd21e799917, content=好倒霉哦！我看我是个日本编辑Fumiyoshi Yamashita.，刚刚分配的，该不会也不友好吧！唉！静等吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2be5614278, createdName=ms4000000786391399, createdTime=Fri Dec 29 14:25:17 CST 2023, time=2023-12-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2118278, encodeId=7b8421182e883, content=千万别投这个，超级浪费时间，我是被分配到日本编辑，with editor 2个多星期，没有送审，最后还是直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=70d05574935, createdName=ms9000000173292023, createdTime=Wed Mar 08 14:24:38 CST 2023, time=2023-03-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2141800, encodeId=7a71214180039, content=日本编辑真的。。。。快两周，不送审，要拒了，无语 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49bb6565860, createdName=ms7000000230836793, createdTime=Fri Jun 09 00:48:09 CST 2023, time=2023-06-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1217328, encodeId=c4ec121e3288c, content=请问这个杂志快不快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0ce8104658, createdName=ms4000000757843752, createdTime=Fri May 06 12:30:02 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922387, encodeId=027c92238e62, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：小硕第一次投IJP,一审小修, 两个审稿意见,一个拒了, 一个提了点关于补充文献的问题, 然后二审有惊无险, 二审required review completed后又under review 3天仲裁去了, 随后接受 时间节点: Received 17 November 2020, Revised 5 January 2021, Accepted 31 January 2021, Available online 2 February 2021., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lLjNEmtiacOgliciaHOQ51Bkuhdy65x8Ciaax4S8cLBObsqrXYBiacsyBmmLhN6ictV4TWVVFPQCcKvN8dcEhSKPicb8w/132, createdBy=94812480651, createdName=lbhaihyh, createdTime=Wed Feb 03 09:09:53 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089655, encodeId=03311089655f2, content=关键词筛选有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089656, encodeId=94de10896563b, content=关键词最多不能超过多少个？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969471, encodeId=35ab9694e186, content=想问一下是否收网络药理学文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a3a5400973, createdName=背包客-Y, createdTime=Sat May 29 17:08:41 CST 2021, time=2021-05-29, status=1, ipAttribution=)]

2021-12-28 ms6000000264964247

关键词最多不能超过多少个？

125 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2197400, encodeId=8a42219e400e0, content=偏重的研究方向：靶向药物;药学 经验分享：6天拒了，日本编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9f0d5508964, createdName=ms7000000724576513, createdTime=Mon Apr 08 16:03:00 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2092620, encodeId=8ac7209262069, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：8月1号投稿 8月9号送审 8月28号初审意见回来，三个审稿人都挺友好，补了个溶血性实验，重拍了电镜，小修了语法9月13日返修回杂志。 10月4日二审意见返回来，要求小修，5号修改完成提交后，10月6日接受 是韩国编辑，挺友好的，实验室由他接手的文章已中了两篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e085589992, createdName=ms6000001711124234, createdTime=Sun Oct 09 10:03:52 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177999, encodeId=9cbd21e799917, content=好倒霉哦！我看我是个日本编辑Fumiyoshi Yamashita.，刚刚分配的，该不会也不友好吧！唉！静等吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2be5614278, createdName=ms4000000786391399, createdTime=Fri Dec 29 14:25:17 CST 2023, time=2023-12-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2118278, encodeId=7b8421182e883, content=千万别投这个，超级浪费时间，我是被分配到日本编辑，with editor 2个多星期，没有送审，最后还是直接拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=70d05574935, createdName=ms9000000173292023, createdTime=Wed Mar 08 14:24:38 CST 2023, time=2023-03-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2141800, encodeId=7a71214180039, content=日本编辑真的。。。。快两周，不送审，要拒了，无语 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49bb6565860, createdName=ms7000000230836793, createdTime=Fri Jun 09 00:48:09 CST 2023, time=2023-06-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1217328, encodeId=c4ec121e3288c, content=请问这个杂志快不快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0ce8104658, createdName=ms4000000757843752, createdTime=Fri May 06 12:30:02 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922387, encodeId=027c92238e62, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：纳米药物;脂质体 经验分享：小硕第一次投IJP,一审小修, 两个审稿意见,一个拒了, 一个提了点关于补充文献的问题, 然后二审有惊无险, 二审required review completed后又under review 3天仲裁去了, 随后接受 时间节点: Received 17 November 2020, Revised 5 January 2021, Accepted 31 January 2021, Available online 2 February 2021., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lLjNEmtiacOgliciaHOQ51Bkuhdy65x8Ciaax4S8cLBObsqrXYBiacsyBmmLhN6ictV4TWVVFPQCcKvN8dcEhSKPicb8w/132, createdBy=94812480651, createdName=lbhaihyh, createdTime=Wed Feb 03 09:09:53 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089655, encodeId=03311089655f2, content=关键词筛选有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089656, encodeId=94de10896563b, content=关键词最多不能超过多少个？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969471, encodeId=35ab9694e186, content=想问一下是否收网络药理学文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a3a5400973, createdName=背包客-Y, createdTime=Sat May 29 17:08:41 CST 2021, time=2021-05-29, status=1, ipAttribution=)]

2021-05-29 背包客-Y

想问一下是否收网络药理学文章

135 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务